Celyad Oncology Announces Third Quarter 2022 Financial Results and Recent Business Highlights
10 nov. 2022 01h01 HE
|
Celyad Oncology SA
Company continues to transition business focus to monetizing unique cell therapy intellectual property and prioritizing R&D discoveryClinical updates expected by end of year for the Phase 1...
Lavras Gold’s Third Quarter Marked by Discovery
07 nov. 2022 16h45 HE
|
Lavras Gold Corp
The news release should be read in conjunction with our unaudited interim consolidated financial statements and management’s discussion and analysis for the period ended September 30, 2022. Both are...
Ashton Woods USA L.L.C. Announces Quarterly Results Conference Call
30 sept. 2022 09h00 HE
|
Ashton Woods Homes
Alpharetta, Ga., Sept. 30, 2022 (GLOBE NEWSWIRE) -- ASHTON WOODS USA L.L.C. ANNOUNCES QUARTERLY RESULTS CONFERENCE CALL Ashton Woods USA L.L.C. (the “Company”) announced today that the...
Connexa Sports Technologies Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
26 sept. 2022 08h00 HE
|
Connexa Sports Technologies Inc.
Baltimore, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Connexa Sports Technologies Inc. (NASDAQ: CNXA) (www.connexasports.com) (the “Company”) announced that it had received a letter from The Nasdaq Stock...
FirstBank Closes Out Second Quarter with Sustained Growth and Top Workplace Ranking
15 août 2022 10h15 HE
|
FirstBank
LAKEWOOD, Colo., Aug. 15, 2022 (GLOBE NEWSWIRE) -- FirstBank, one of the nation’s largest privately held banks with a focus on “banking for good,” announced continued growth in assets, deposits and...
Immatics veröffentlicht Ergebnisse des zweiten Quartals 2022 sowie ein Update zur Geschäftsentwicklung
09 août 2022 07h00 HE
|
Immatics N.V.
Patientenrekrutierung in allen drei Phase-1b-Studienkohorten mit ACTengine® IMA203 TCR-T-Zelltherapiekandidaten (Zielstruktur: PRAME) gestartet: IMA203 Monotherapie mit vorläufiger, empfohlener...
Immatics Announces Second Quarter 2022 Financial Results and Business Update
09 août 2022 07h00 HE
|
https://immatics.com/
ACTengine® TCR-T cell therapy targeting PRAME is enrolling patients in all three Phase 1b cohorts: IMA203 monotherapy at provisional recommended Phase 2 dose (RP2D) (Cohort A), IMA203/nivolumab...
CAPSTONE INFRASTRUCTURE CORPORATION REPORTS SECOND QUARTER RESULTS AND DECLARES A QUARTERLY DIVIDEND
08 août 2022 16h40 HE
|
Capstone Infrastructure Corporation
Toronto, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Capstone Infrastructure Corporation (TSX: CSE.PR.A) (the "Corporation" or "Capstone") today announced and filed its financial results for the second...
Immatics veröffentlicht Ergebnisse des ersten Quartals 2022 sowie ein Update zur Geschäftsentwicklung
02 juin 2022 07h05 HE
|
Immatics N.V.
ACTengine® IMA203: Erste Patienten mit empfohlener Zieldosis in Phase-1b-Kohorte A mit IMA203-Monotherapie sowie Kohorte B mit IMA203 und Checkpoint-Inhibitor behandelt; Studienzulassung (IND...
Immatics Announces First Quarter 2022 Financial Results and Business Update
02 juin 2022 07h05 HE
|
https://immatics.com/
ACTengine® IMA203: First patients treated at RP2D in Phase 1b cohort A with IMA203 monotherapy as well as Phase 1b cohort B with IMA203/checkpoint inhibitor combination. IND for Phase 1b cohort C with...